Adagio Medical Holdings, Inc. 8-K

What Happened
Adagio Medical Holdings, Inc. announced in an 8‑K (Item 8.01) that it submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration on May 21, 2026 for the vCLAS® Ventricular Ablation System to treat ventricular tachycardia. The company issued a press release describing the submission, which is attached to the filing as Exhibit 99.1.

Key Details

• Submitted a PMA to the FDA on May 21, 2026 for the vCLAS® Ventricular Ablation System.
• Indication named in the filing: treatment of ventricular tachycardia (VT).
• Announcement made via press release included as Exhibit 99.1 to the Form 8‑K.

Why It Matters
A PMA submission is a major regulatory milestone for a medical-device company: FDA acceptance and eventual approval would be required before commercial sales in the U.S. for the vCLAS system to treat VT. For investors, the filing advances Adagio’s regulatory pathway and is a key event to monitor for updates on FDA review status, timelines, and any subsequent corporate disclosures; however, submission is not approval and outcomes remain contingent on the FDA review process.